Dr Rob Dow has extensive experience of the Biopharma, Biotechnology and CRO sectors. Rob has worked on drug development in most therapeutic areas, and held senior positions including Chief Medical Officer and executive and non-executive board positions for both UK and US companies.
Dr Rob Dow completed his undergraduate education at St Andrews and Dundee University, and after qualifying spent seven years training in internal medicine in clinical pharmacology, cardiology and diabetes and endocrinology at Ninewells Hospital and working in the Department of Clinical Pharmacology and Therapeutics for Professor James Crooks.
Rob then joined the pharmaceutical industry, working for fifteen years for Syntex Corporation in the UK and California, and then Hoffman La Roche in Switzerland, where he held the position of Global Head of Drug Development. During that time, he gained substantial experience in managing the transition of over twenty drugs from pre-clinical to clinical development, as well as playing a key role in the full development and approval of nicardipine hydrochloride for angina and hypertension and mycophenolate mofetil for kidney, heart and liver transplantation. During these years he managed toxicology, pharmacokinetics, data management and statistics, project management, clinical science, clinical operations, regulatory affairs and drug safety departments.
Rob then spent the next eleven years in the Biotechnology sector, first as CEO for a public UK company (Scotia Holdings) and then a private UK company (Biolitec Pharma) where he successfully obtained a centralised EMEA approval for a novel product for head and neck cancer and went on to supervise pricing, reimbursement and the commercial launch of the product in several European countries. He was also a non-executive director of Oxford Asymmetry, a public UK company. He then served as Chief Medical Officer of a San Francisco based company (Cell Genesys Inc) where he led the development programme for an immunotherapy treatment for prostate cancer.
Rob has spent the last eleven years working for PPD Inc, a global CRO. He held several executive positions and for the last three years was Chief Medical Officer. He was also a Board Member of X-Rx Inc, a privately-held US-based biotechnology company
With his extensive experience of the Biopharma, Biotechnology and CRO sectors, Rob is now keen to work with early phase biotechnology companies, either as a Board Member or providing advisory services covering due diligence, drug development and clinical trial planning, portfolio prioritisation and CRO selection and management.
If you would like to speak to Rob you can contact email@example.com
Free services supported by paid for services. If you or any of your contacts are considering engaging a recruiter, consultant or trainer we will welcome the opportunity to be considered.